Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
1321-1340 of 2,251 trials

Vulvar Squamous Cell Carcinoma: Pembrolizumab Study

We are studying whether Pembrolizumab can help shrink tumors in patients with vulvar squamous cell carcinoma before surgery. This trial also looks at how the treatment affects the immune system.

Vulvar Squamous Cell Carcinoma1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

IgG4-Related Disease: Abatacept Treatment Study

We are investigating whether abatacept can help reduce the risk of disease recurrence in people with IgG4-related disease. This study aims to provide insights into a new treatment option for managing this condition.

IgG4-Related Disease>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicineRheumatology

Kidney Health: CO2 Injection in Vascular Procedures

We are testing a new method using Carbon Dioxide instead of traditional contrast media for patients at risk of kidney injury during vascular interventions. This study aims to see if it can help prevent serious kidney problems after the procedure.

Peripheral Arterial Disease (PAD)>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteCardiologyNephrology

Shingrix Vaccine: Safety in Psoriasis and Psoriatic Arthritis

We are studying the safety and immune response of the Shingrix vaccine in patients with psoriasis or psoriatic arthritis. Our goal is to see how the vaccine affects disease activity and to monitor any side effects.

Psoriatic ArthritisPsoriasis Vulgaris>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteAllergologyDermatology

Advanced Cancers with BRAF Mutations: Sorafenib and Trametinib Study

We are testing a combination of two medications for patients with advanced-stage cancers that have BRAF mutations. The goal is to find the best dose and understand how well this treatment works and its safety.

Advanced-Stage Cancer with BRAF Mutation>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncology

Primary Adrenal Insufficiency: Plenadren vs. Cortisone

We are investigating how treatment with Plenadren affects quality of life compared to cortisone in individuals aged 16-80 newly diagnosed with primary adrenal insufficiency.

Primary Adrenal Insufficiency>2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteEndocrinology

Metastatic Renal Cell Carcinoma: Temferon Gene Therapy

We are testing a new gene therapy using modified stem cells for patients with metastatic renal cell carcinoma. The study aims to evaluate the safety and biological response to a single dose of Temferon.

Metastatic Kidney Cancer1-2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Bladder Cancer: EG-70 Treatment Study

We are testing a new treatment called EG-70 for patients with bladder cancer that hasn't responded to standard therapy. The study aims to see if it can help improve outcomes and quality of life for these patients.

Non-muscle invasive bladder cancer>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncologyUrology

Acute Heart Failure: Intra-Abdominal Pressure and Ultrasound Study

We are exploring whether using intra-abdominal pressure and ultrasound can improve diuretic treatment for patients with acute heart failure. This study aims to see if these methods help reduce congestion and improve recovery compared to standard treatment.

Acute Heart Failure>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCardiologyInternal Medicine

Multiple Sclerosis: ABP 692 vs. Ocrevus

We are comparing a new treatment called ABP 692 with Ocrevus for people with relapsing-remitting multiple sclerosis. The goal is to see how they differ in effectiveness and safety.

Relapsing-Remitting Multiple Sclerosis>2 yearsConfirmation phase (III)16-20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementNeurology

EGL-001 for Advanced Solid Tumors

We are testing a new treatment called EGL-001 in adults with advanced or metastatic solid tumors. The study aims to evaluate its safety and effectiveness, both alone and with another medication.

Advanced and Metastatic Solid Tumors1-2 yearsSafety phase (I)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Advanced Breast Cancer: PF-07220060 with Letrozole

We are studying a new medicine, PF-07220060, combined with letrozole for adults with HR-positive, HER2-negative advanced breast cancer. This trial compares its effectiveness to standard treatments in patients who haven't had prior systemic therapy.

Advanced/Metastatic Breast CancerConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Sepsis Treatment: New Antibiotic Dosing Strategy

We are testing a new way to dose beta-lactam antibiotics for critically ill patients with sepsis. The goal is to see if this improves their recovery in the ICU.

Sepsis1-2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesInternal MedicinePulmonology

Lung Cancer: Sacituzumab and Zimberelimab Treatment

We are studying a combination of two medications for patients with non-small cell lung cancer who have had surgery but are not disease-free. The goal is to see if this treatment can help prevent cancer from returning.

Resectable Non-small Cell Lung CancerConfirmation phase (III)No PlaceboInvestigational MedicinesOncologyPulmonology

B-Cell Non-Hodgkin Lymphoma: BI-1206 Treatment Study

We are studying a new monoclonal antibody combined with rituximab, with or without acalabrutinib, for patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The goal is to assess safety and how well it may work in reducing cancer cells.

Indolent B-Cell Non-Hodgkin Lymphoma3-6 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Esophageal Adenocarcinoma: The PRESTO Trial

We are studying a combination of durvalumab and chemoradiation to see if it can help preserve the esophagus in patients with early-stage cancer. This trial aims to avoid surgery and assess treatment effectiveness and safety.

Esophageal Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Metastatic Colorectal Cancer: Telisotuzumab Adizutecan Study

We are investigating a new treatment combination for people with metastatic colorectal cancer to see if it works better and is safer than current standard treatments.

Metastatic Colorectal Cancer≤3 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Ovarian Cancer: Continued Treatment with Olaparib

We are providing ongoing treatment with Olaparib for patients who have benefited from it in a previous study. This trial focuses on monitoring safety while allowing continued access to the medication.

Ovarian CancerBreast CancerProstate Cancer>2 yearsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

ENPP1 Deficiency: INZ-701 Study

We are investigating whether the drug INZ-701 can help infants with ENPP1 deficiency by improving survival and preventing heart and respiratory problems. The study aims to see if it can also support physical growth and reduce artery issues.

Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Deficiency1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyPediatrics

Non-Small Cell Lung Cancer: Acasunlimab and Pembrolizumab Study

We are evaluating a new combination treatment for patients with advanced non-small cell lung cancer who have already received other therapies. The goal is to see if this combination works better than the standard treatment, docetaxel.

Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology